HERC5 Polyclonal antibody
HERC5 Polyclonal Antibody for IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse
Applications
IP, CoIP, ELISA
Conjugate
Unconjugated
Cat no : 22692-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IP detected in | HEK-293 cells |
Recommended dilution
Application | Dilution |
---|---|
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
KD/KO | See 1 publications below |
WB | See 4 publications below |
CoIP | See 2 publications below |
Product Information
22692-1-AP targets HERC5 in IP, CoIP, ELISA applications and shows reactivity with human, mouse samples.
Tested Reactivity | human, mouse |
Cited Reactivity | human, mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | HERC5 fusion protein Ag18449 |
Full Name | hect domain and RLD 5 |
Calculated Molecular Weight | 1024 aa, 117 kDa |
Observed Molecular Weight | 117 kDa |
GenBank Accession Number | BC140716 |
Gene Symbol | HERC5 |
Gene ID (NCBI) | 51191 |
RRID | AB_2879151 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen Affinity purified |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
IP protocol for HERC5 antibody 22692-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
J Clin Invest Posttranslational ISGylation of NLRP3 by HERCs enzymes facilitates inflammasome activation in models of inflammation
| ||
Adv Sci (Weinh) Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer |